APLM.US Apollomics Inc. Class A Ordinary Shares

Healthcare Biotechnology USA Stocks
17.68 USD
Close of Nov 13, 2026
12.58 28.29
Market cap
USD 51.5M
P/E
-
P/B
8.12x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is APLM.US undervalued?

Graham number

The Graham number of Apollomics Inc. Class A Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Apollomics Inc. Class A Ordinary Shares fundamental analysis

No fundamental analysis for Apollomics Inc. Class A Ordinary Shares yet.

Apollomics Inc. Class A Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Apollomics Inc. Class A Ordinary Shares

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral acti…

Full company profile